

WHO-sponsored preliminary review indicates Ivermectin effectiveness

Meta-analysis of clinical trials of ivermectin to treat COVID-19 infection



Dr Andrew Hill,
Department of Pharmacology,
University of Liverpool, UK



ACTaccelerator
ACCESS TO COVID-19 TOOLS



Published: December 31, 2020 (upd.)


Share on: [Twitter](#) / [Facebook](#)

WHO-sponsored review of ivermectin trials indicates 83% reduction in covid mortality.

Dr Andrew Hill of the Department of Pharmacology at the University of Liverpool (UK) is currently performing a WHO-sponsored review and meta-analysis of randomized controlled trials of ivermectin against covid. In the following [12-minute video](#), Dr Hill is presenting his preliminary results, which indicate a highly significant **83% reduction in covid mortality** (95% CI 65%-92%).

This result is based on in-hospital trials, so it does not yet take into account early ambulatory and prophylactic treatment. The authors of the review intend to include three more trials, due to be published sometime in January, before providing a final conclusion. At the end of his presentation, Dr Hill describes ivermectin as a potentially “transformational treatment”.

See also: [Overview of all covid-19 ivermectin studies \(IVMMETA\)](#)



See also

- [On the treatment of Covid-19](#)
- [On post-acute \(“long”\) Covid](#)
- [Facts about Covid-19](#)

Share on: [Twitter](#) / [Facebook](#)